UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the

Securities Exchange Act of 1934

May 4, 2012 Date of Report (Date of earliest event reported): May 3, 2012

ISTA PHARMACEUTICALS, INC.

(Exact name of registrant as specified in its charter)

Delaware

001-35396

33-0511729

(State or other jurisdiction

of incorporation)

(Commission

File Number)

(IRS Employer

Identification No.)



50 Technology Drive, Irvine, California				92618
(Address of principal executive offices)				(Zip Code)

Registrant’s telephone number, including area code: (949) 788-6000

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

¨	Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425).

¨	Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

¨	Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

¨	Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Item 2.02

Results of Operations and Financial Condition.

On May 3, 2012, ISTA Pharmaceuticals, Inc. issued a press release to report its financial results for the quarters ended March 31, 2012 and 2011, respectively. The release is furnished as Exhibit 99.1 hereto and incorporated herein by this reference.

The information in this Current Report on Form 8-K, including Exhibit 99.1, is furnished pursuant to Item 2.02 and shall not be deemed “filed” for the purposes of Section 18 of the Securities Exchange Act of 1934, as amended, or otherwise subject to the liability of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, except as shall be expressly set forth by specific reference in such a filing.

Item 9.01

Financial Statements and Exhibits.

(d)	Exhibits.


Exhibit Number		Description

99.1		Press release, dated May 3, 2012.

Signatures

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

EXHIBIT INDEX


Exhibit Number		Description

99.1		Press release, dated May 3, 2012.

ISTA PHARMACEUTICALS, INC.

May 4, 2012

/s/ Lauren P. Silvernail

Chief Financial Officer and Vice President, Corporate Development

ISTA PHARMACEUTICALS INC 8-K